Knight Therapeutics (GUD) Q2 2025 earnings summary

Executive summary

• Achieved record-high adjusted revenues of CAD 197 million for H1 2025, with 15% organic growth on a constant currency basis driven by promoted products.

• Q2 2025 adjusted revenues reached CAD 108.5 million (USD 108.5 million), up 15% year-over-year, or 21% on a constant currency basis.

• Expanded product portfolio by over 50 products through Paladin and Sumitomo transactions, including key launches and regulatory submissions, strengthening the Canadian business.

• Expanded agreements with Helsinn and Incyte, adding innovative oncology products and advancing regulatory submissions and approvals in key markets.

• Net loss widened to CAD 5.7 million (USD 12.6 million) in Q2, mainly from mark-to-market revaluations and higher expenses.

Financial highlights

• Q2 2025 revenues reached CAD 108.5 million (USD 108.5 million), up 15% year-over-year; constant currency growth was 21%.

• Adjusted EBITDA for Q2 2025 was CAD 15.5 million (USD 15.5 million), relatively unchanged year-over-year; per share was CAD 0.16 (USD 0.16).

• Gross margin was CAD 49 million (USD 49.4 million), 46% of adjusted revenue, down from 48% due to product mix, severance, and hyperinflation accounting.

• Net debt position at quarter-end was CAD 6.5 million, with CAD 91.2 million (USD 91.2 million) in cash and marketable securities.

• Cash inflow from operations was USD 20.3 million, reversing a prior outflow.

Outlook and guidance

• Fiscal 2025 revenue guidance raised to CAD 410–420 million (USD 410–420 million), driven by strong H1 performance and Sumitomo transaction.

• EBITDA expected to remain at approximately 13% of revenues.

• Guidance assumes no material impact from hyperinflation in Argentina, no major supply disruptions, and successful execution of new product launches.

• Anticipates step-ups in EBITDA margin in 2026–2028 as new product launches scale.